IMS, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries released the annual "U.S. Pharmaceutical Market Performance Review" which found that pharmaceutical market growth slowed from 8% in 2006 to 3.8% in 2007. According … Continue reading
If a tree falls in the forest, and almost no one notices, did the tree almost not fall? Pharmaceutical Executive noticed, but I didn’t notice anyone else notice. I’m talking about the long-proposed user fee program for the FDA’s Division … Continue reading
One of the many confounding things about the AIDS epidemic is the radical shift of the HIV disease burden to populations of countries with the least ability to payfor therapy. That creates a number of dilemmas and conundrums. One, those … Continue reading
I was fascinated to read the RPM Report analysis of the new system that will emerge when the new FDA bill is signed into law. A new user fee program for review of DTC ads will exist that allows the … Continue reading
I have written several postings in the past on uses of social media by pharmaceuticals. Just last week, I had a posting on Fard Johnmar’s excellent White Paper on the legal aspects of social media by pharmaceuticals. One idea that … Continue reading
